Evaluating the impact of a rheumatologist-led comorbidity review in patients with inflammatory arthritis
Authors' conclusion
Rheumatologist-led comorbidity reviews can improve care in IA, particularly for interventions allowing direct action.
Study context
- Population
- Adults with rheumatoid arthritis (RA) or spondyloarthritis (SpA) undergoing a standardized rheumatologist-led comorbidity review (EULAR and local guidelines), tertiary care hospital, June 2017-March 2025
- Participants
- 458 vs 63
- Exposure
- Adherence to comorbidity recommendations before vs after the first rheumatologist-led review
- One reviewn = 458
- Two reviewsn = 63
- Outcome
- Baseline compliance with comorbidity management recommendations and clinical impact of the structured review
Methodological detailssingle-centre (tertiary care hospital), before-after comparison in patients with two reviews
- Single-centre (tertiary care hospital)
- Before-after comparison in patients with two reviews
Main finding
As reported in the abstract
Baseline care gaps
Elevated LDL
44.6%
Vitamin D deficiency
75.1%
Influenza vaccination
54.0%
DTP vaccination
55.7%
Observational data: associations, not effects.
Further findings
Actions following the review
- Received vaccine prescriptions
- 62.5%
- Referred to cardiology
- 5.6%
Change before vs after first review (patients with two reviews)
- Vitamin D deficiency, 82.0% to 42.0%
- P < 0.001
- Influenza vaccination, 42.1% to 68.4%
- P = 0.003
- DTP vaccination, 57.4% to 75.4%
- P = 0.035
- Dermatology screening for skin cancer, 45.2% to 58.1%
- P = 0.039
- Cardiovascular risk factors remained largely unchanged
Original publication
Evaluating the impact of a rheumatologist-led comorbidity review in patients with inflammatory arthritis. Joint Bone Spine. Published 23 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →